In patients with multiple sclerosis, there is continuous loss of the insulating myelin sheath that wraps around neurons and increases the speed of impulses in the central nervous system. Whenever neurons are demyelinated, OPCs migrate toward these cells and differentiate into mature, myelin-producing oligodendrocytes, but this process becomes less and less effective as people age.
A nuclear receptor protein called retinoid X receptor gamma (RXR gamma) is known to promote OPC differentiation and remyelination, but, because nuclear receptors generally function in pairs, a team of researchers led by Robin Franklin at the University of Cambridge, UK, set out to identify RXR gamma's binding partners and investigate their possible role in remyelination.
‘Researchers at University of Cambridge, UK, set out to identify RXRgamma's binding partners and investigate their possible role in remyelination.’
RXR gamma; bound to several nuclear receptors, including VDR, in OPCs and mature oligodendrocytes. Inhibiting VDR impaired OPC differentiation and reduced the cells' ability to remyelinate axons ex vivo. In contrast, Vitamin D, which binds and activates VDR, boosted OPC differentiation.
Low vitamin D levels have been linked to the onset of multiple sclerosis, and the researchers' findings suggest that the vitamin might also affect disease progression by controlling myelin sheath regeneration, a critical step to alleviate the disease's symptoms that fails as patients age. VDR-activating drugs might therefore be able to enhance remyelination in multiple sclerosis patients and in patients suffering from other demyelinating diseases.